Searched for
PEPTIDE MANUFACTURING
Aragen steps up investment in complex drug modalities; plans 500 KL new CDMO capacityAragen Life Sciences is increasing investments in complex drug modalities and manufacturing. The company plans to add significant small-mol...- Karnataka food safety officials seize expired, mislabelled products from Amazon, Instamart units in BengaluruIn a recent crackdown, authorities in Karnataka uncovered significant violations at Amazon and Instamart facilities. During unannounced ins...
- Exclusive | How Vijay Kedia turned a Rs 250 Neuland Labs bet into nearly 100x returnsInvestor Vijay Kedia's savvy investment in Neuland Laboratories has paid off handsomely, yielding nearly 100x returns. He seized the opport...
- Growing peptide trend raises safety concerns among doctorsDoctors express concern over popular injectable peptides for various health benefits. They caution that established peptide medicines diffe...
- How PGIM India's Rs 112 crore Healthcare Fund picks CDMO stocks to generate alphaPGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...
- Jefferies initiates coverage on Anthem Biosciences with a Rs 1,050 targetJefferies has initiated coverage on Anthem Biosciences with a Buy rating and Rs 1,050 target, implying around 20% upside. The brokerage is ...
- Picking the right pharma stock is getting harder; so pick a portfolio: 20 stocks with -23% to +22% downside to upside potentialFor Indian pharma, the regulatory risk is still real. A US FDA inspection can still cause trouble. A plant making an important product or g...
- Government tightens surveillance on GLP-1 weight-loss drug promotion amidst surrogate advertising concernsCentral government directs state regulators to enhance surveillance over GLP-1 drug promotion. Approved GLP-1 drugs are only for Type 2 dia...
- India pharma sector to miss 2030 sales target amid tariff and shipping woes, trade body saysIndia's pharmaceutical industry is expected to reach$80-90 billion by 2030, well below its earlier$130 billion target, as U.S. tariff uncer...
- Piramal Pharma to focus on policy, not Trump tariff tweets: Nandini PiramalPiramal Pharma will focus on policy actions amid tariff concerns. Its global manufacturing network offers a significant advantage. The comp...
- Tariff on generic drugs: Loud announcement, little consequence? 7 pharma stocks with upside potential of up to 31%The threat of a US tariff on Indian pharma is no longer a vague fear; or at least that is what President Trump wants us to believe. There i...
- Laurus Labs shares rally over 4% as Q1FY27 profit jumps 126% on strong CDMO growthLaurus Labs reported a strong June-quarter performance, with net profit more than doubling and revenue rising 29% year-on-year, driven by r...
- Cipla expects sequential recovery in North America on new product launches despite tariff uncertaintyCipla reported a 39% drop in net profit to ₹789 crore for the June quarter due to weakness in its North America business and margin compres...
- 'Chinese peptides' are the latest biohacking trend in the tech worldTech professionals are embracing unapproved Chinese peptides for weight loss, fitness, and productivity. These substances, often sourced di...
- Granules India shares in focus on acquiring Swiss firm for Rs 192 crGranules India has acquired Swiss CDMO company Senn Chemicals AG for Rs 192 crore, expanding its peptide therapeutics market presence. The ...
- Granules acquires Swiss firm for Rs 192 cr; forays into CDMO spaceGranules India has acquired Swiss CDMO firm Senn Chemicals AG for CHF 20 million, expanding into the peptide therapeutics segment. The acqu...
- Self-assembling anti-cancer molecules created in minutesResearchers have developed a simple and versatile method for making artificial anti-cancer molecules that mimic the properties of one of th...
- Peptide is an emerging field in pharma: Venkat R Kalavakolanu, CMD, Jupiter BioscienceIn a chat with ET Now, Venkat R Kalavakolanu, CMD, Jupiter Bioscience, talks about the peptide business.
- Indian drug cos prepare a peptide mixAs blockbuster drugs are set to lose exclusivity in the US, Indian pharma companies are gearing up to tap the fast-growing generic peptide ...
- Ranbaxy, Jupiter Bioscience enter into marketing tie-upRanbaxy Laboratories is about to enter into a 10-year co-marketing agreement with Jupiter Bioscience to tap the $6-billion global peptide p...
Load More
